Skip to content

Opus Genetics, Inc.: 10-K filed 2019-03-07

What Opus Genetics, Inc. reported in its annual report filed 2019-03-07 (fiscal FY 2018): 26 published measures, 90 facts as tagged in accession 0001140361-19-004539.

This filing

Form
10-K (annual report)
Filed
2019-03-07
Fiscal period
fiscal FY 2018
Accession
0001140361-19-004539 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Opus Genetics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-12-3116,042,926USD
At 2017-12-3128,287,881USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-12-315,480,036USD
At 2017-12-3111,519,285USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-12-3110,562,890USD
At 2017-12-3116,768,596USD
At 2016-12-3117,058,462USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-12-318,744,301USD
At 2017-12-318,899,154USD
At 2016-12-3111,578,473USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-10-01 to 2018-12-31-3,116,570USD92
2018-01-01 to 2018-12-31-14,368,530USD365
2018-07-01 to 2018-09-30-5,338,819USD92
2018-04-01 to 2018-06-30-3,838,268USD91
2018-01-01 to 2018-03-31-2,074,873USD90
2017-10-01 to 2017-12-31-3,592,463USD92
2017-01-01 to 2017-12-31-25,294,503USD365
2017-07-01 to 2017-09-30-1,038,072USD92
2017-04-01 to 2017-06-30947,056USD91
2017-01-01 to 2017-03-31-21,611,024USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-18,838,638USD365
2017-01-01 to 2017-12-31-15,420,055USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-01-01 to 2018-12-316,772,789USD365
2017-01-01 to 2017-12-3122,113,514USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-01-01 to 2018-12-3111,910,996USD365
2017-01-01 to 2017-12-31-9,372,778USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-12-31-154,687,242USD
At 2017-12-31-140,318,712USD

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2017-10-01 to 2017-12-31-0.12USD/shares92
2017-07-01 to 2017-09-30-0.04USD/shares92
2017-04-01 to 2017-06-300.04USD/shares91
2017-01-01 to 2017-03-31-0.91USD/shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2017-10-01 to 2017-12-31-0.12USD/shares92
2017-07-01 to 2017-09-30-0.04USD/shares92
2017-04-01 to 2017-06-300.03USD/shares91
2017-01-01 to 2017-03-31-0.91USD/shares90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-12-31112,473USD
At 2017-12-31121,460USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-01-01 to 2018-12-311,228,335USD365
2017-01-01 to 2017-12-311,044,167USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-10-01 to 2018-12-31-4,966,470USD92
2018-01-01 to 2018-12-31-20,537,673USD365
2018-07-01 to 2018-09-30-4,683,907USD92
2018-04-01 to 2018-06-30-5,001,441USD91
2018-01-01 to 2018-03-31-5,885,855USD90
2017-10-01 to 2017-12-31-4,898,229USD92
2017-01-01 to 2017-12-31-17,354,717USD365
2017-07-01 to 2017-09-30-4,219,322USD92
2017-04-01 to 2017-06-30-4,283,925USD91
2017-01-01 to 2017-03-31-3,953,241USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-12-3115,899,668USD
At 2017-12-3128,135,636USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2018-10-01 to 2018-12-314,966,470USD92
2018-01-01 to 2018-12-3120,537,673USD365
2018-07-01 to 2018-09-304,683,907USD92
2018-04-01 to 2018-06-305,001,441USD91
2018-01-01 to 2018-03-315,885,855USD90
2017-10-01 to 2017-12-314,898,229USD92
2017-01-01 to 2017-12-3117,354,717USD365
2017-07-01 to 2017-09-304,219,322USD92
2017-04-01 to 2017-06-304,283,925USD91
2017-01-01 to 2017-03-313,953,241USD90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-01-01 to 2018-12-3113,109,058USD365
2017-01-01 to 2017-12-3110,715,296USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-12-3137,527,420shares
At 2017-12-3131,725,114shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2018-12-31-17,836USD
At 2017-12-31-56,886USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2018-12-31821,590USD
At 2017-12-31833,306USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2018-12-31709,117USD
At 2017-12-31711,846USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2018-12-311,173,847USD
At 2017-12-311,304,541USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-14,329,480USD365
2017-01-01 to 2017-12-31-25,345,267USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-01-01 to 2018-12-317,428,615USD365
2017-01-01 to 2017-12-316,639,421USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2018-10-01 to 2018-12-311,849,900USD92
2018-01-01 to 2018-12-316,169,143USD365
2018-07-01 to 2018-09-30-654,912USD92
2018-04-01 to 2018-06-301,163,173USD91
2018-01-01 to 2018-03-313,810,982USD90
2017-10-01 to 2017-12-311,305,766USD92
2017-01-01 to 2017-12-31-7,939,786USD365
2017-07-01 to 2017-09-303,181,250USD92
2017-04-01 to 2017-06-305,230,981USD91
2017-01-01 to 2017-03-31-17,657,783USD90

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2018-01-01 to 2018-12-316,872,789USD365
2017-01-01 to 2017-12-3116,681,921USD365

Inspect the source

Entity
Opus Genetics, Inc. / CIK 0001228627
Captured
2026-09-20T07:46:24.028Z
SEC response SHA-256
59b3f548361fa5c66fb8bd927bac9bc7dc8822bcce158860c7c4d77974af0a92

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001228627.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))